06 May 2015

NICE, Level 1, City Tower, Piccadilly Plaza, Manchester

The meeting will start promptly at 10:00 and is expected to finish at approximately 17:00

Please note that this agenda is subject to change prior to the meeting.

Final Agenda

  1. Welcome and introduction to format of meeting
  2. Apologies
  3. Any other business
  4. Minutes from the last Committee meeting held on 1 April 2015.
  5. Appraisal of Degarelix for treating advanced hormone-dependent prostate cancer
    5.1. Declarations of interest - Part 1 only (open session)
    5.2. Introduction by the Chair, Professor Gary McVeigh - Part 1 only (open session)
    5.3. Presentation by the Chair, Professor Gary McVeigh -Part 1 AND part 2 (open and closed session)
    5.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) - Part 2 only (closed session)
  6. Appraisal of Radium-223 dichloride for treating metastatic hormone relapsed prostate cancer with bone metastases
    6.1. Declarations of interest - Part 1 only (open session)
    6.2. Introduction by the Chair, Professor Gary McVeigh - Part 1 only (open session)
    6.3. Presentation by the Chair, Professor Gary McVeigh   -Part 1 AND part 2 (open and closed session)
    6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) - Part 2 only (closed session)
  7. Appraisal of Ombitasvir/paritaprevir/ritonavir with or without dasabuvir for treating chronic hepatitis C 

7.1. Declarations of interest - Part 2 only (closed session)
7.2. Introduction by the Vice Chair, Dr Lindsay Smith - Part 2 only (closed session)
7.3. Presentation by the Vice Chair, Dr Lindsay Smith   -Part 2 only (closed session)
7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) - Part 2 only (closed session)

8. Appraisal of Ledipasvir-sofosbuvir for treating chronic hepatitis C

8.1. Declarations of interest - Part 2 only (closed session)
8.2. Introduction by the Chair, Professor Gary McVeigh - Part 2 only (closed session)
8.3. Presentation by the Chair, Professor Gary McVeigh   -Part 2 only (closed session)
8.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) - Part 2 only (closed session)

9. Discussion of Hepatitis C topics: Ombitasvir/paritaprevir/ritonavir with or without dasabuvir, Ledipasvir-sofosbuvir and Daclatasvir, in the context of the NHS England comments received on the consultation for the preliminary recommendations for Ledipasvir-sofosbuvir. Part 2 only (closed session)

Date of next meeting
Next Technology Appraisal (Committee D) Meeting: Wednesday 3 June 2015 10:00am, NICE, Level 1, City Tower, Piccadilly Plaza, Manchester, M1 4BT.

Please note all timings are approximate.

To print the agenda, please right click and select 'Print' from the menu

To register

You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.

The closing date for registration is 21 April 2015 for sessions 1-6. Sessions 7-9 the closing date is 28 April 2015. 

Please note that late registration requests cannot be accepted.

Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Lee Berry

Please note that registrants wishing to conduct a research study on the committee meeting and/or NICE processes will require prior permission and should contact NICE Enquiry Handling by email nice@nice.org.uk further information about conducting research is also available in our Common Questions and Answers about meetings in public document

 

Registration period: 07 to 28 April 2015
Registration is closed.